Chunfen Zhang

Mrs. Chunfen Zhang

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
LSLucy Swift
Lucy Swift
CZChunfen Zhang
Chunfen Zhang
TTTanya Trippett
Tanya Trippett
ANAru Narendran
Aru Narendran
Purpose: Neuroblastoma is the most common extracranial cancer in children. Although the prognosis for low-risk neuroblastoma patients is good, the 5-year survival rates for high-risk and relapsed patients are low. The poor survival rates for these patients demonstrate the need for novel therapeutic approaches to treat this disease. PV-10 is a sterile 10% solution of Rose Bengal that has previously been shown to induce cell death in a range of adult cancers, providing the rationale for studying the activity of PV-10 against neuroblastoma in preclinical studies. Methods: The effects of PV-10 on neuroblastoma were investigated in vitro. Cytotoxicity assays were performed using the alamar blue assay on the following cell lines: SK-N-AS, SK-N-BE(2), IMR5, LAN1, SHEP, and SK-N-SH neuroblastoma cells, SK-N-MC neuroepithelioma cells, and normal primary, BJ, and WI38 fibroblasts. Phase-contrast, fluorescence, and time-lapse video microscopy; flow cytometry; and Western blotting were used to investigate the effects of PV-10 on SK-N-AS and IMR5 cells. Synergy with commonly used anticancer drugs was determined by calculation of combination indices in SK-N-AS and IMR5 cells. Mouse xenograft models of SK-N-AS and IMR5 tumors were also used to evaluate the efficacy of PV-10 in vivo. Results: In vitro preclinical data demonstrate that pharmacologically relevant concentrations of PV-10 are cytotoxic to neuroblastoma cell lines. Studies to investigate target modulation in neuroblastoma cell lines show that PV-10 disrupts lysosomes, decreases the percentage of cells in S phase, and induces apoptosis in a concentration-, time-, and cell-line-dependent manner, and we also identify agents that are synergistic with PV-10. Furthermore, experiments in xenograft mouse models show that PV-10 induces tumor regression in vivo. Conclusion: Our study provides preclinical data on the efficacy of PV-10 against neuroblastoma and provides rationale for the development of an early phase clinical trial of this agent in relapsed and refractory neuroblastoma patients.

8 October 2023 in Genes
Verified
Journal Article
Open access
PDF file
RSRitul Sharma
Ritul Sharma
CZChunfen Zhang
Chunfen Zhang
ANAru Narendran
Aru Narendran
The E26-transformation-specific (ETS) transcription factors regulate multiple aspects of the normal hematopoietic system. There is an increasing body of evidence suggesting aberrant ETS activity and its contribution to leukemia initiation and progression. In this study, we evaluated the small-molecule ETS inhibitor TK216 and demonstrated its anti-tumor activity in pediatric leukemia. We found TK216 induced growth inhibition, cell cycle arrest and apoptosis and inhibited the migratory capability of leukemic cells, without significantly inhibiting the cell viability of normal blood mononuclear cells. Priming the leukemic cells with 5-Azacitidine enhanced the cytotoxic effects of TK216 on pediatric leukemia cells. Importantly, we found purine-rich box1 (PU.1) to be a potential target of TK216 in myeloid and B-lymphoid leukemic cells. In addition, TK216 sharply decreased Mcl-1 protein levels in a dose-dependent manner. Consistent with this, TK216 also potentiated the cytotoxic effects of Bcl-2 inhibition in venetoclax-resistant cells. The sustained survival benefit provided to leukemic cells in the presence of bone-marrow-derived conditioned media is also found to be modulated by TK216. Taken together, our data indicates that TK216 could be a promising targeted therapeutic agent for the treatment of acute myeloid and B-lymphoid leukemia.

16 April 2024 in Cancers
Verified
Journal Article
Open access
PDF file
STSon Tran
Son Tran
PSPatrick Sipila
Patrick Sipila
STSatbir Thakur
Satbir Thakur
CZChunfen Zhang
Chunfen Zhang
ANAru Narendran
Aru Narendran
PV-10 is a 10% formulation of rose bengal sodium that has potent immunotherapeutic and anti-cancer activity against various tumors, including metastatic melanoma and refractory neuroblastoma. Currently, PV-10 is undergoing clinical testing for refractory metastatic neuroendocrine cancer and melanomas. However, preclinical investigation of PV-10 activity and its mechanisms against phenotypically and molecularly diverse adult solid tumors had not been conducted. In a panel of human cell lines derived from breast, colorectal, head and neck, and testicular cancers, we demonstrated that PV-10 induces cytotoxicity by apoptotic and autophagic pathways involving caspase-mediated PARP cleavage, downregulation of SQSTM1/p62, and upregulation of beclin-1. Treatment with PV-10 also consistently reduced phosphorylation of WNK1, which has been implicated in cancer cell migration and autophagy inhibition. By wound healing assay, PV-10 treatment inhibited the migration of cancer cells. Finally, significant inhibition of tumor growth was also noted in tumor-bearing mice treated with PV-10 by intralesional or systemic administration. In addition to known PV-10-mediated tumor-specific cytotoxic effects, we identified the mechanisms of PV-10 and provide new insights into its effect on autophagy and metastasis. Our data provide essential mechanism-based evidence and biomarkers of activity to formulate clinical studies of PV-10 in the future.

1 April 2012 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
JFJames Edwin Fewell
James Edwin Fewell
CZChunfen Zhang
Chunfen Zhang
Newly born animals of a number of species have an increased cardiac glycogen content compared to older animals which is purported to support cardiac function and promote survival during hypoxia. As a first step in investigating the role of cardiac glycogen in influencing protective responses of newly born rat pups to hypoxia, our experiments were carried out to determine if cardiac glycogen would be altered following isoproterenol(ISO)‐induced transient tachycardia. In preliminary dose–response experiments testing doses of 0 to 10 mg/kg of the nonselective beta adrenergic receptor agonist ISO, we determined 1.25 mg/kg to be the smallest dose that elicited a maximal heart rate response (i.e., the EC 100 ) in 1 day‐old pups and in which the heart rate returned back to control levels by 120 minutes. One day old rat pups received vehicle (VEH) or ISO (1.25 mg/kg) ip and heart rate was recorded for 120 min before decapitation and removal of the heart for determination of glycogen content. Whole heart glycogen content in untouched pups was 4.1±0.5 mg/g of tissue (n=4). Whole heart glycogen content decreased significantly (p<0.05) following ISO‐induced transient tachycardia compared to VEH: 1.5±0.5 mg/g (n=8) versus 3.5±0.3 mg/g (n=5), respectively. Thus, our data provide evidence that whole heart glycogen is significantly decreased in newly born rat pups following ISOinduced transient tachycardia.